Switch Therapeutics
James Treanor is an accomplished executive and advisor with extensive experience in the biotechnology and pharmaceutical sectors. Currently serving as an Advisor and SAB member for Karma Biotechnologies and Switch Therapeutics, as well as holding board member and CEO roles at ADRx, Inc., James Treanor has demonstrated leadership in various capacities since 2014. Previous positions include Chief Scientific Officer at Neuron23 and several senior roles at Amgen, where James Treanor was a Scientific Executive Director and Group Leader. Early in the career at Genentech, James Treanor completed a postdoctoral research position in Neuroscience. Academic qualifications include a Ph.D. in Molecular Neurobiology from the University of Bristol and a B.Sc (Hons) in Applied Biology from the University of East London.
This person is not in any teams
Switch Therapeutics
Switch Therapeutics is an emerging biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science, with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet need. The CASi (Conditionally Activated siRNA) platform, the company’s novel gene knockdown approach, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School and City of Hope. CASi combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity.